ARIKAYCE Instructions For Use
PARI Pharma's eFlow® Technology device, LAMIRA™, approved as the only nebulizer system to deliver Insmed's ARIKAYCE® (amikacin liposome inhalation suspension)
Oral Inhaled Medications—Beyond Bronchodilators
Pharmaceutical liposomal delivery—specific considerations of innovation and challenges - Biomaterials Science (RSC Publishing) DOI:10.1039/D2BM01252A
Track Record - PARI
Lamira - PARI
Dosing | ARIKAYCE® (amikacin liposome inhalation suspension)
Pari Pharma lands FDA nod for Lamira nebulizer - MassDevice
Inhalation mit dem Lamira® Inhalationssystem - YouTube
Nebulizer Market Size to Surpass USD 1,202.5 Million by 2029, exhibiting a CAGR of 4.8%
Global Inhalation Therapy Nebulizer Market Is Likely To Grow At A CAGR Value Of Around 7.5% By 2028
New Drug Product: Arikayce - MPR
Prescribing ARIKAYCE (amikacin liposome inhalation suspension)
ARIKAYCE Instructions For Use
eFlow Technology Platform - PARI
ARIKAYCE® Prescription and Arikares® Support Program Enrollment Form
207356Orig1s000
ARIKAYCE Instructions For Use
LAMIRA®, an eFlow® Technology nebulizer, expected to launch in Japan as a medical device for exclusive administration of ARIKAYCE® (amikacin liposome inhalation suspension)
Vibrating Mesh Nebulizer Market Size, Demand, Insight - 2031
BUY Amikacin (Arikayce) 590 mg/8.4mL from GNH India at the best price available.
